Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 6:02 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: G2-TR intraocular implant containing travoprost, Sham surgery + active-comparator eye drops; Combination Product · Drug
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 590 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Ocular Hypertension
Interventions: bimatoprost/timolol fixed combination; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Hypertension, Depression
Interventions: Mobile Health Monitoring; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 80 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hypertension
Interventions: herbal therapy/botanical therapy (Hibiscus sabdariffa); Behavioral
Lead sponsor: Tufts University; Other
Eligibility: 30 Years to 70 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glaucoma
Interventions: Sterile commercially available bandage contact lens, Medical grade silicone of a thickness >100 µm, Medical grade silicone of a thickness <100 µm with blur tint, Standard tip in conjunction with a topical anesthetic; Diagnostic Test
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetes Mellitus, Cardiovascular Diseases, Hypertension
Interventions: Centralized support for population health management activities; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 108,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Kidney Disease, Hypertension
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Glaucoma
Interventions: Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%; Drug
Lead sponsor: Innovative Medical; Industry
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Angina, Pulmonary Arterial Hypertension
Interventions: Ranolazine; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atherosclerosis, Diabetes Mellitus, Obesity, Dyslipidemia, Hypertension
Interventions: Exercise, Weight Loss; Behavioral
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Preeclampsia
Interventions: SAIL; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Wauwatosa, Wisconsin

Conditions: Pulmonary Arterial Hypertension
Interventions: Inhaled Nitric Oxide; Drug
Lead sponsor: Geno LLC; Industry
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 2
States / cities: Birmingham, Alabama • Pittsburgh, Pennsylvania

Conditions: Pulmonary Arterial Hypertension, Frailty
Interventions: Low-Resistance Training; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Endothelial Dysfunction
Interventions: Potato, Non-starchy vegetable; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 45 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes, Coronary Artery Disease, Hypertension
Interventions: Service based decision support intervention; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Wellesley, Massachusetts

Conditions: Pulmonary Arterial Hypertension
Interventions: Oral treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 41
States / cities: Fresno, California • Los Angeles, California • San Juan Capistrano, California + 37 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Inhaled Nitric Oxide 75 mcg/kg IBW/hr, Placebo; Drug
Lead sponsor: Bellerophon Pulse Technologies; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 37
States / cities: Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 33 more

Conditions: Hypertension
Interventions: Carvedilol CR capsules, Placebo, Lisinopril; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 65 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 20
States / cities: Anniston, Alabama • Glendale, Arizona • Anaheim, California + 17 more

Conditions: Gestational Hypertension
Interventions: Nokia-Withings BPM Connect Blood Pressure Monitor, Smartwatch Devices; Device
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Obesity, Insulin Resistance, Hypertension, Metabolic Cardiovascular Syndrome
Interventions: Angiotensin-(1-7), Saline; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hypertension, Cardiovascular Diseases, Diabetes Mellitus, Metabolic Syndrome X
Interventions: Not listed
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 2,072 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Sleep Apnea, Insufficient Sleep Syndrome, Sleep, Hypertension
Interventions: PAP Treatment, Sleep Education I; Behavioral
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years and older
Enrollment: 561 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Pulmonary Arterial Hypertension
Interventions: Imatinib mesylate, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 3
States / cities: Los Angeles, California • Newark, New Jersey • New York, New York

Conditions: Hypertension (HTN), Chronic Stress
Interventions: Behavioral: B-MORE (Brief Mindfulness-Oriented Recovery Enhancement); Behavioral
Lead sponsor: Florida State University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Orlando, Florida

Search by objective public record fields.

Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%

Safety and Efficacy Study of Bimatoprost/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

PERsonal ContExtual Precision healTh

The Effect of Hibiscus Sabdariffa L. Tea on Blood Pressure

Tolerability of an Anesthesia-free Tonometer Tip

Implementation of a Population Health Chronic Disease Management Program

ADMA Levels in End-Stage Renal Disease

Bimatoprost Monotherapy vs. Dual Therapy With Travoprost and Timolol in Patients With Glaucoma and Ocular Hypertension

Ranolazine and Pulmonary Hypertension

Effects of Worksite Wellness Interventions on Vascular Function, Insulin Sensitivity and High-Density Lipoprotein in Overweight or Obese Women

Social Risks-Focused Lifestyle Intervention to Reduce Preeclampsia (SAIL)

Study to Assess Acute Vasodilation Response of Inhaled Nitric Oxide

Safety and Impact of Low Resistance Exercise Training on Quality of Life in Pulmonary Arterial Hypertension

Potatoes, Hypertension RIsk and Endothelial Function Study

Clinical Decision Support Consortium

ADAPT - A Patient Registry of the Real-world Use of Orenitram®

Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH

Evaluation of Potential for Orthostatic Hypotension in Elderly Hypertensives

Digital Solutions to Reduce Maternal Morbidity and Mortality in Pregnant Refugee Women

Metabolic Effects of Angiotensin-(1-7)

Cardiovascular Disease Risk Factors in Chinese American Immigrants

Improving Outcomes for Patients With SDB and Insufficient Sleep

Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension

Dual-Language B-MORE for Hypertension